The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ARCHIVE
ARCHIVE
- Efco, Kyuyukai to Merge in Fall
June 4, 2001
- WORLD NEWS IN BRIEF
May 28, 2001
- Kyowa Hakko: Drug Sales Down to \141.4 Bil. Due to Suspension of Acenalin Shipment
May 28, 2001
- Industry Must Accept Price Reduction for Long-listed Products: Health Minister
May 28, 2001
- Anti-epileptic Zonisamide to Be Effective against Parkinson's Disease
May 28, 2001
- Teijin: Pharmaceutical Sales Up 1.6% to \88.6 Bil.
May 28, 2001
- None of the Current Proposals Stabilizes Health Insurance Finance: Kenporen Simulation
May 28, 2001
- Seijo: Sales Up 15%, Operating Profits Down 3%
May 28, 2001
- Kobayashi Pharmaceutical: Record-high Sales, Profits
May 28, 2001
- REGULATORY NEWS IN BRIEF
May 28, 2001
- PAJ's Council on Self-medication Promotion to Start Discussions in June
May 28, 2001
- Long-Term Incentives Are Essential to Develop New Drugs: Dr McKinnell
May 28, 2001
- Keidanren, Nikkeiren Propose Senior Healthcare System
May 28, 2001
- JSMBE Advocates IT Revolution in BME
May 28, 2001
- Eisai Reorganizes R&D System to Accelerate Clinical Trials in Japan
May 28, 2001
- Benefits under Government-managed Health Insurance Down 1.7% to \4,207.6 Bil.
May 28, 2001
- Fresenius Completes New CAPD System Plant in Buzen
May 28, 2001
- Securities Analyst Recommends Win-win M&As to Domestic Drug Companies
May 28, 2001
- Yamanouchi to Tie Up with Hitachi for Genomic Drug Discovery
May 28, 2001
- BSJ: New Product in Maverick Series
May 28, 2001
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…